Galicia's cost-cutting drug catalogue challenged by Spanish government in court
This article was originally published in Scrip
Executive Summary
Spain's central government is to appeal against an autonomous regional authority that has introduced its own reimbursement list for medicines, which differs from the centrally approved list. The pharmaceutical industry is likely to pay close attention to the case, which could affect whether other regional authorities break rank with central pricing and reimbursement policies to create an increasingly uncertain market.